For Bronchiectasis

Unlock the critical symptom of cough with objective monitoring

Cough is not just a symptom in bronchiectasis; it is one of the most distressing and persistent clinical features.

  • Up to 90% of patients with bronchiectasis report daily coughing, often with sputum production¹

  • Frequent cough is strongly linked to poorer quality of life, increased airway infection risk, and higher healthcare utilization.²

  • Traditional measures (spirometry, imaging, and patient-reported outcomes) often fail to capture the real-world frequency, severity, and timing of cough.³

For drug developers and clinicians, this gap presents both a clinical challenge and an opportunity: objective cough monitoring can provide granular insights into how treatments impact patient lives.

Technology Overview

The RESP® Biosensor is a leading, high-fidelity cough monitoring technology designed for measuring treatment effects on cough in patients’ daily lives. Our technology offers:

  • A wireless, discreet design that respects patient comfort and lifestyle
  • Direct cloud syncs that expedite analysis of cough measures and streamline patient reports
  • Novel measures, such as cough intensity, that lead to a greater understanding of overall cough burden
Certifications: FDA 510(k) clearance, CE Mark, HIPAA Compliant
Strados Cough Monitoring Solution

Why the RESP® Biosensor for Bronchiectasis Patients?

Privacy & Security

Incorporates end-to-end encryption and speech obfuscation to preserve patient privacy

Wireless Data Sync

Cloud-based syncs from paired mobile phones allow for remote data uploads, accelerating subject reporting

High Fidelity & Accuracy

FDA 510(k) class II medical device for capturing lung sounds, including cough

Patient-Friendly

Wireless, discreet biosensor secured by a gentle and breathable adhesive

Advanced Insights

Gain a greater understanding of cough burden beyond cough counts, including cough intensity, breathing patterns, vitals, and other physiological data.

For Clinicians

  • Track cough as a biomarker of exacerbation risk⁴

  • Identify worsening symptoms earlier, supporting timely interventions

  • Extend visibility into patients’ day-to-day experience outside the clinic

Learn More

For Life Sciences

  • Demonstrate treatments meaningfully reduce cough burden

  • Support patient-centric outcomes that reflect how patients feel and function

  • Integrate objective cough data alongside PROs and clinical measures

Learn More

Publications

Explore our peer reviewed performance testing, studies and publications.

Cough Detection Performance of the CoughCheck Algorithm in Subjects with Subacute Cough

Objective Cough Monitoring Detects More Patients with Cough Than Patient Self-Reporting
Results of Clinical Performance Testing in Chronic Lung Diseases
View All Publications

OVERVIEW VIDEO

Learn more about the benefits of the RESP® Biosensor for Bronchiectasis patients 

Let’s Connect

Explore using the RESP® Biosensor in your study or practice

Contact Us

References

  1. Spinou A, Lee KK, et al. The validity of the Leicester Cough Questionnaire in bronchiectasis. Eur Respir J. 2017;49(3):1601532.
  2. Chalmers JD, et al. The impact of chronic cough in bronchiectasis: relationship to disease severity, quality of life, and exacerbations. Chest. 2014;145(5):974–982.
  3. McGuinness G, Naidich DP. Bronchiectasis: CT evaluation. AJR Am J Roentgenol. 2002;179(5):1241–1248.
  4. Guan W, et al. Symptoms predict future risk of exacerbations in adults with bronchiectasis: a multicentre prospective cohort study. Lancet Respir Med. 2025. doi:10.1016/S2213-2600(25)00160-2